Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC decreased its position in shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by 1.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,790 shares of the company’s stock after selling 480 shares during the period. Oak Ridge Investments LLC owned about 0.06% of Biohaven Pharmaceutical worth $2,583,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BHVN. US Bancorp DE purchased a new stake in Biohaven Pharmaceutical during the 4th quarter worth about $25,000. Valeo Financial Advisors LLC increased its holdings in Biohaven Pharmaceutical by 195.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 295 shares of the company’s stock worth $25,000 after purchasing an additional 195 shares during the period. Canada Pension Plan Investment Board increased its holdings in Biohaven Pharmaceutical by 120.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 363 shares of the company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Lazard Asset Management LLC purchased a new stake in Biohaven Pharmaceutical during the 4th quarter worth about $53,000. Finally, WASHINGTON TRUST Co increased its holdings in Biohaven Pharmaceutical by 137.5% during the 1st quarter. WASHINGTON TRUST Co now owns 950 shares of the company’s stock worth $65,000 after purchasing an additional 550 shares during the period. 92.11% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE BHVN opened at $103.46 on Friday. The firm has a market cap of $6.73 billion, a PE ratio of -7.30 and a beta of 1.01. Biohaven Pharmaceutical Holding Company Ltd. has a 52-week low of $57.66 and a 52-week high of $103.83. The firm has a 50-day moving average price of $76.81.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Sunday, May 9th. The company reported ($4.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.92) by ($1.29). The business had revenue of $43.82 million during the quarter, compared to the consensus estimate of $36.46 million. During the same period last year, the firm earned ($2.39) earnings per share. The company’s revenue for the quarter was up 3710.4% compared to the same quarter last year. On average, research analysts predict that Biohaven Pharmaceutical Holding Company Ltd. will post -13.47 earnings per share for the current fiscal year.

BHVN has been the topic of a number of recent analyst reports. Mizuho increased their price objective on Biohaven Pharmaceutical from $90.00 to $92.00 and gave the company a “buy” rating in a report on Friday, May 28th. UBS Group initiated coverage on Biohaven Pharmaceutical in a report on Thursday, March 11th. They issued a “buy” rating and a $108.00 price objective on the stock. Morgan Stanley dropped their price objective on Biohaven Pharmaceutical from $76.00 to $69.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 18th. Piper Sandler increased their price objective on Biohaven Pharmaceutical from $90.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, March 1st. Finally, Cantor Fitzgerald increased their price objective on Biohaven Pharmaceutical from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, June 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $100.45.

In related news, Director John W. Childs acquired 13,157 shares of the firm’s stock in a transaction on Wednesday, March 17th. The stock was bought at an average cost of $76.00 per share, with a total value of $999,932.00. 15.20% of the stock is currently owned by company insiders.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Article: What does earnings per share mean?

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.